Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-15

Clinical Trial Update: Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients [Phase 2]

View source ↗

Summary

Phase 2 study updating pharmacokinetics and optimal dosing of ertapenem in patients with end-stage renal disease undergoing hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ERTAPENEM (ertapenem)

Snippet

Sponsor: Corewell Health East | Conditions: End Stage Renal Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-06-15